1. Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment. (12th November 2020) Authors: Reddy, R.; Pannu, S.; Fiumara, K.; Kahn, J.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment. (1st March 2021) Authors: Reddy, R.; Pannu, S.; Fiumara, K.; Kahn, J.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Hailey–Hailey disease treated with dupilumab: a case series. (1st September 2021) Authors: Alzahrani, N.; Grossman‐Kranseler, J.; Swali, R.; Fiumara, K.; Zancanaro, P.; Tyring, S.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Hailey–Hailey disease treated with dupilumab: a case series. (5th July 2021) Authors: Alzahrani, N.; Grossman‐Kranseler, J.; Swali, R.; Fiumara, K.; Zancanaro, P.; Tyring, S.; Rosmarin, D. Journal: British journal of dermatology Issue: Volume 185:Number 3(2021) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗